GREENVILLE, SC, UNITED STATES, February 11, 2026 /EINPresswire.com/ —
• ATC-002 is a topical treatment designed to stimulate new hair growth in subjects with androgenic alopecia.
• ATC-002 uses Atticus’s proprietary Z-pod® technology to create a drug depot in the hair follicle and stratum corneum to deliver drug in a sustained-release manner.
• ATC-002 was evaluated in a cosmetic claims substantiation clinical trial in a 6-month, 3-arm, randomized, double-blind, placebo-controlled study in 98 women in the U.S.
• This First-in-Human study provided clear evidence of therapeutic effect and unremarkable safety and tolerability, both supporting continued clinical development.
Atticus Pharma Inc., a therapeutics company focused on immunodermatology and other skin disorders, today announced data from a clinical study of ATC-002 in females with androgenic alopecia. ATC-002 is a proprietary product candidate that delivers a mitochondrial-activating molecule using Atticus’s Z-pod sustained-release technology.
The study was a 6-month, 3-arm, randomized, double-blind, placebo-controlled study in 98 women in the U.S. Subjects were randomly assigned to receive: (i) a low dose of ATC-002, (ii) a high dose of ATC-002, or (iii) placebo. The main objectives of the study were to assess systemic safety and local tolerability as well as exploring dose response and subject baseline characteristics associated with optimal therapeutic response.
Overall, all study treatments were safe and well tolerated. Topical application of ATC-002 was associated with terminal hair growth at both doses. In particular, the high dose resulted in a mean increase of 13.8 hairs/cm2 in subjects with more hair loss as measured by vellus to terminal hair ratios. The increase in hair growth continued between the 3-month and the final 6-month timepoints, suggesting that future trials of longer duration will show even greater gains. Importantly, the study subject’s global satisfaction questionnaire was highly consistent with the objective hair count findings.
“Demonstrating significant new hair growth in androgenic alopecia subjects that had a challenging baseline ratio of vellus to terminal hair is exciting,” said Atticus CEO, Leigh Hsu, Ph.D. “We are extremely pleased with the findings from this study as they inform the next stage of clinical development and supports a clear regulatory pathway for a future Rx that can treat a condition affecting 80 million Americans.” Hsu added, “It’s also very encouraging that ATC-002 safety and tolerability were unremarkable because drugs for androgenic alopecia are generally used long-term, so a clean safety profile is critical to assure treatment compliance.”
About Atticus Pharma.
Atticus Pharma was established in 2024 to advance the pharmaceutical applications of the Z-pod technology. Atticus is also advancing ATC-001 for cutaneous lupus. Atticus plans to expand capabilities of its platform technology through partnerships with companies that are active in immunodermatological diseases. Learn more at: www.atticuspharma.com.
Forward-Looking Statements.
This press release contains “forward-looking statements” of Atticus Pharma Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Atticus’s beliefs and expectations concerning: the safety, efficacy, success and advancement of its clinical programs for ATC-002; and its growth as a company and expectations regarding its uses of capital, expenses, future accumulated deficit and financial results.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Atticus’s ability to protect and maintain its intellectual property position; risks related to Atticus’s relationship with third parties, including its contract manufacturers, collaborators, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to the authorization, initiation and conduct of preclinical and clinical studies and other development requirements for its product candidates, including uncertainties related to regulatory approvals to conduct clinical trials; risks related to the ability to develop and commercialize any one or more of Atticus’ product candidates successfully; risks related to the results of preclinical studies or clinical studies not being predictive of future results in connection with future studies; the risk that clinical study results will not be positive; risks related to the potential delay of planned clinical trials due to regulatory feedback or other developments; and risks related to Atticus’s collaborations not continuing or not being successful. All information in this press release is as of the date of the release, and Atticus undertakes no duty to update this information unless required by law.
Contact: Leigh Hsu
Atticus Pharma Inc.
hello@atticuspharma.com
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
